TGFB1 and neoplasm: One such rare target is the Transforming Growth Factor-beta (TGF-β), which has not been considered as a favorable target for cancer treatment due to its dual role in promoting or inhibiting tumor growth, depending on the tumor stage and cellular context [75,76].